SynthesisMolecular psychiatry2026
Rethinking Alzheimer's: novel miRNAs illuminate a disease beyond the brain.
Synthesis in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Non-coding RNAs and Mitochondrial Dysfunction in Alzheimer's Disease: A Systematic Review.Molecular neurobiology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) poses major health, social and economic challenges to the modern world. Despite the advances in understanding AD, our knowledge about its pathogenesis remains incomplete. Recent data suggest that circulating microRNAs (miRNAs) undergo complex changes in AD. Since these changes are yet to be comprehensively characterized, we investigated miRNAs in the context of AD using two meta-analytical approaches. We reproducibly identified 2895 miRNAs in a cohort of 4186 individuals from 22 studies. Here we show that 194 miRNAs exhibited widespread changes in AD, including some novel miRNAs not yet linked to AD. These novel AD miRNAs broaden the landscape of research on the role of miRNAs in AD. Targets of these miRNAs further uncovered many biological pathways that, to date, remain poorly understood in AD with several "AD miRNAs" never described in the brain. "AD miRNAs" described outside the brain significantly influenced interleukin signaling, Toll receptor signaling, p38 MAPK pathway and insulin/IGF pathway. Our results reveal a greater complexity of biological pathways involved in AD than previously thought and raise the question of whether AD is indeed a brain-specific and not a systemic disorder. These findings advance current understanding of AD pathogenesis and lay the ground for the development of next-generation AD biomarkers and design of miRNA-engaged therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.